A decade ago the term renovascular disease implied unilateral renal artery stenosis as a treatable cause of hypertension'-'0. Surgical or percutaneous interventional treatment can restore normal blood pressure without need for medication'1. Since then the focus has switched to atheromatous renovascular disease (ARVD) as a cause of renal failure. One reason is the greying of the dialysis population, with acceptance of patients into their 70s or even 80s on dialysis programmes; in perhaps 20% of the over-65s starting dialysis, a cause of the renal failure will be artery disease12-16. Another reason is the widespread use of angiotensin converting enzyme (ACE) inhibitors for the treatment of hypertension, heart failure and diabetic nephropathy, which has unmasked disease in a cohort of patients whose renal artery stenosis might otherwise have lain dormant17. Unfortunately this explosion of awareness has not been matched by a better understanding of the natural history or by formulation of clear goals for intervention. Thus, our knowledge of ARVD resembles that of carotid and coronary artery disease before the largescale trials clarified therapeutic goals and strategies for intervention.
PRESENTATIONS OF ATHEROMATOUS RENOVASCULAR DISEASE ARVD presents in seven ways: * Hypertension * Flash pulmonary oedema * Acute renal failure * Chronic renal failure * Atheroembolic disease * Incidental finding at angiography * Necropsy Figure 1 , based on necropsy data, shows that bilateral renal artery stenosis is very common in the old18. (Hypertension is listed purely for completeness; it is only rarely caused by renal artery stenosis and, in the absence of other pointers, investigations for ARVD are not indicated'9.) ARVD should be sought actively in a patient with arterial disease at other sites, aged 60 or over, who has any degree of renal impairment with little or no blood or protein in the urine, absence of inflammatory markers, and evidence of unilateral or bilateral renal shrinkage on ultrasonography. In a recent study of patients fulfilling these criteria, over half the patients proved to have greater than 75% renal artery stenosis on at least one side and one-fifth had bilateral disease20.
NATURAL HISTORY
Five clinicopathological scenarios arise in ARVD. First, there may be critical deterioration in renal function after treatment with an ACE inhibitor. Revascularization by surgery or angioplasty produces long-term improvement in renal function.
Second, renal function declines despite revascularization, because of progressive glomerulosclerosis and nephrosclerosis. Patients unlikely to respond to revascularization have a renal length of less than 9 cm21, poor function on quantitative renography22, a serum creatinine greater than 400 1umol/L23-25 and renal biopsy showing greater than 40% glomerulosclerosis26'27* Third, some patients who have what appears to be critical disease remain stable without intervention. Presumably they have developed a collateral circulation; this area of renal anatomy is poorly studied.
Fourth, arteriography demonstrates unilateral occlusion by atheroma with a normal main renal artery on the other side. In some of these patients renal function progressively declines, perhaps because of small vessel occlusion within KidneyUnit,oyalevonadExetrHosital,xeterX25D,Englnd 31 the kidney or more likely atheroembolic disease of the remaining kidney28. The final scenario is death despite intervention, because of atheromatous disease elsewhere. This has been observed also in carotid artery studies where, in both control and treated groups, the main cause of death is coronary artery disease. The cynic might say that the main objective in atherosclerotic disease should be to delay the onset of renal failure long enough for the patient to die of cardiac or cerebral disease.
Although several studies have documented progression of renal failure in ARVD29,30, there are no reliable predictors save perhaps very high grade stenosis30, in which progression is inevitable. The challenge is to avoid unnecessary intervention (on the basis of renal artery anatomy alone) in patients who will either never develop critical renal failure or who will progress despite intervention.
RENAL ARTERY DISEASE AND RENAL FAILURE
As many as 15% of patients reaching end-stage renal failure have a component of renal ischaemia 2'3133. With the continuing fall in coronary and cerebral vascular deaths a growing number of patients will survive to present with renal failure due to ARVD. The impact of ARVD on a dialysis programme has been reported by Mailloux et aP32.
In elderly patients ARVD is the commonest single cause of renal failure, more common than either diabetes or glomerulonephritis ( Figure 2 ).
Kalra et a131 reported that, of 530 patients with acute renal failure presenting to a single renal unit over six years, 16% had renovascular disease as the underlying cause. In a quarter of these cases renal failure had been triggered by the use of a converting enzyme inhibitor. The number of such cases is likely to grow with the more widespread use of ACE inhibitors in hypertensive, cardiac and diabetic patients. In diabetic patients one has to be cautious that the beneficial impact on glomerulosclerosis is not negated by the adverse haemodynamic consequences of the use of ACE inhibitors in a population at high risk of renal atheroma.
RENOVASCULAR DISEASE: GOALS OF TREATMENT
In many studies of intervention in ARVD the end-point has been renal artery patency rate, on the assumption that if a renal artery is patent dialysis will be avoided. But how many of these patients would require dialysis without intervention? We know that the incidence of renal failure in the population up to age 80 is 80-100 per million per annum34, while necropsy studies show significant ARVD in 20% of over-65s18. Thus, even if as many as 20 per million per annum have ARVD as the cause of renal failure, it is obvious that the great majority of patients with the disorder will never be at risk of developing terminal renal failure. Most patients will die with their renal artery stenosis rather than of it. Certain populations have proved to have an enormously high incidence of ARVD for example, 20-40% of patients undergoing leg angiography for claudication35-39 and 10-25% of patients undergoing coronary arteriography4042. If these patients are routinely screened for renal artery stenosis there is a danger that many more patients will be identified and inappropriately treated, merely on the basis of angiographic appearances. The true goals of treatment for ARVD are prolongation of life and maintenance of quality of life (which can largely be achieved by preservation of renal function). A reason for erring on the side of intervention is the high cost of maintenance dialysis. Renal replacement therapy costs between £15000 and £20 000 a year, and few patients with this cause of renal failure will be suitable for renal transplantation. Even if these patients survive poorly on dialysis, by preventing one person from reaching end-stage renal failure we might save in excess of £30 000 over the remaining lifetime for that patient; so it might be costeffective to intervene in 30 patients at a cost of £1000 each to prevent one case of renal failure. Unfortunately we do not know the threshold for intervention, either clinical or radiographic.
CHALLENGES
The key questions to which we need answers are: * Which patients should be screened * When they should be screened * How they should be screened * When should we intervene * How should we intervene * What additional therapeutic interventions are required (e.g. statin drugs, aspirin)
Perhaps the greatest challenge is to define criteria for intervention that, in addition to renal angiography, include factors such as absolute renal function, the rate of decline of kidney function, absolute renal size, the rate of shrinkage of the kidney on ultrasound, and renal histology.
CONCLUSIONS
The patients at greatest risk of renal failure are those whose kidney function declines abruptly on exposure to an ACE inhibitor. Whether all at-risk patients can ethically be challenged with one of these drugs is not yet clear, but this strategy may be acceptable as a way of defining a subpopulation in which intervention is mandatory.
For many patients, close observation of renal function (as judged by serum creatinine) and renal size (as assessed by serial ultrasound measurements) may be preferable to angiography and intervention. The greatest area of potential gain, however, may lie in attention to cardiac risk factors and a rigorous search for coronary and carotid disease in patients with renal artery disease. The findings of the 4S study43 may be relevant to renal artery disease. Perhaps patients with unilateral renal artery stenosis should be entered into a trial of statin against placebo, where the endpoints are not just renal function and renal size but also coronary morbidity and mortality.
With coronary artery disease, peripheral vascular disease, aortic aneurysm and carotid disease we know where we are going, but with ARVD the story is only just beginning to unfold. ARVD is the fifth frontier for vascular therapy.
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